Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Scripps Research scientists find new way to attack cancerous cells

08.06.2010
The findings open the door to the development of more effective therapies for lymphomas and leukemias

Scripps Research Institute scientists have discovered a new way to target and destroy a type of cancerous cell. The findings may lead to the development of new therapies to treat lymphomas, leukemias, and related cancers.

The study, which appears in the June 10, 2010 edition of the journal Blood, showed in animal models the new technique was successful in drastically reducing B cell lymphoma, a cancer of immune molecules called B cells.

"[The method] worked immediately," said Scripps Research Professor James Paulson, who led the research. "We are very interested in moving this technology forward to see if it would be applicable to treatment of humans and to investigate other applications for this kind of targeting."

A Sweet Spot

In his research program at Scripps Research, Paulson has studied glycoproteins, which are proteins decorated with sugars, for many years. While these molecules have traditionally proven challenging to understand, limiting their pharmaceutical applications, Paulson has pioneered new techniques to study and manipulate these enigmatic molecules.

In the new research, Paulson and his colleagues applied some of the lab's insights to a problem with great medical relevance—finding a new way to target and destroy cancer cells.

Specifically, in the new study the team set out to attack B cell lymphoma (which includes Hodgkin lymphoma and non-Hodgkin lymphoma), a type of cancer diagnosed most frequently in older individuals and those with compromised immune systems. Each year approximately 70,000 people are diagnosed with B cell lymphomas in the United States alone, according to the American Cancer Society. While the drug rituximab is often effective at treating the disease, each year 22,000 patients still die from B cell malignancies.

Normally, B cells provide an important immune function circulating throughout the bloodstream to help in the attack of infectious agents. But when B cells become cancerous, the question becomes how to pick them out of the crowd of other molecules in the body to target them for destruction, ideally without affecting surrounding tissues.

Because of his previous research, Paulson knew that B cells had a unique receptor protein on their surfaces that recognized certain sugars found on glycoproteins. Could the team create a viable potential therapeutic that carried these same sugars to identify and target these cells?

Toward a "Magic Bullet"

Paulson and colleagues decided to try a unique approach to this problem.

The scientists combined two different types of molecules into one, using both new and tried-and-true technology. One part of the potential therapeutic was composed of a specialized sugar (ligand) recognized by the B cell receptor, called CD22, expressed on the surface of B cells. This was attached to the surface of the other portion of the potential therapeutic, a nanoparticle called a "liposome," loaded with a potent dose of a proven chemotherapy drug.

"The advantage is that we already know a lot about how liposomes act in the body because they are approved drugs," said Paulson. "They have a long circulatory half-life. They are formulated so they are not taken up by the macrophages in the liver. So we just used the same formulation, attached these ligands, and went right into in vivo studies."

The chemotherapy drug chosen was doxorubicin, which is used in the treatment of a wide range of cancers. First identified in the 1950s, doxorubicin was originally isolated from bacteria found in soil samples taken from a 13th-century Italian castle. The team used a nanoparticle formulation of doxorubicin called Doxil, in which the drug is encapsulated inside the liposomal nanoparticle, which Paulson explains protects normal cells from the drug until it reaches the cancer.

Normally Doxil is passively delivered to tumors by exiting leaky tumor vasculature, and the drug slowly leaks out to kill the tumor. But by decorating the nanoparticles with the CD22 ligand, the team made the nanoparticles into a type of Trojan horse that is actively targeted to and taken up by human lymphoma B cells, carrying the drug inside the cell.

In the current research, the team administered their new compound to immune-compromised mice that had been infected with B cell lymphoma cells (Daudi Burkitt type). The team used two different formulations of the molecule, one decorated with two percent ligands, the other with five percent. The mice received only one dose.

The results were remarkable. No mouse in the control group lived to the end of the 100-day trial, but five of the eight mice receiving the higher ligand dose of the compound survived.

The scientists then looked to see if they could detect any residual tumor cells in the survivors, knowing that in a mouse that is paralyzed by the disease 95 percent of the cells in the bone marrow are tumor cells.

"When we looked at the bone marrow of those that had survived to 100 days, we couldn't detect any [tumor cells]," said Paulson. "Our detection limit was down to 0.3 percent. It was pretty impressive."

To extend the results, the scientists examined their compound's activity in blood samples from human patients with three types of B cell lymphomas—hairy cell leukemia, marginal zone lymphoma, and chronic lymphocytic leukemia. The scientists found that the compound also effectively bound to and destroyed these diseased B cells.

Encouraged by the results, the team is now working to further improve the drug platform, looking for ways to increase the specificity of B cell targeting as well as exploring the technology's use with other chemotherapy agents.

The first author of the paper, "In vivo targeting of B-cell lymphoma with glycan ligands of CD22," was Weihsu Chen of Scripps Research. In addition to Paulson, additional authors were Gladys Completo of Scripps Research, Darren Sigal, and Alan Saven of Scripps Clinic Medical Group, and Paul Crocker of the University of Dundee (UK). For more information, see http://bloodjournal.hematologylibrary.org/cgi/content/abstract/blood-2009-12-257386v1

The research was funded by grants from the National Institute of Allergy and Infectious Diseases (NIAID) and the National Institute of General Medical Sciences (NIGMS) of the National Institutes of Health (NIH).

About The Scripps Research Institute

The Scripps Research Institute is one of the world's largest independent, non-profit biomedical research organizations, at the forefront of basic biomedical science that seeks to comprehend the most fundamental processes of life. Scripps Research is internationally recognized for its discoveries in immunology, molecular and cellular biology, chemistry, neurosciences, autoimmune, cardiovascular, and infectious diseases, and synthetic vaccine development. Established in its current configuration in 1961, it employs approximately 3,000 scientists, postdoctoral fellows, scientific and other technicians, doctoral degree graduate students, and administrative and technical support personnel. Scripps Research is headquartered in La Jolla, California. It also includes Scripps Florida, whose researchers focus on basic biomedical science, drug discovery, and technology development. Scripps Florida is located in Jupiter, Florida.

Keith McKeown | EurekAlert!
Further information:
http://www.scripps.edu

More articles from Health and Medicine:

nachricht Penn vet research identifies new target for taming Ebola
12.01.2017 | University of Pennsylvania

nachricht The strange double life of Dab2
10.01.2017 | University of Miami Miller School of Medicine

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Interfacial Superconductivity: Magnetic and superconducting order revealed simultaneously

Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.

While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...

Im Focus: Studying fundamental particles in materials

Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales

Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...

Im Focus: Designing Architecture with Solar Building Envelopes

Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.

As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...

Im Focus: How to inflate a hardened concrete shell with a weight of 80 t

At TU Wien, an alternative for resource intensive formwork for the construction of concrete domes was developed. It is now used in a test dome for the Austrian Federal Railways Infrastructure (ÖBB Infrastruktur).

Concrete shells are efficient structures, but not very resource efficient. The formwork for the construction of concrete domes alone requires a high amount of...

Im Focus: Bacterial Pac Man molecule snaps at sugar

Many pathogens use certain sugar compounds from their host to help conceal themselves against the immune system. Scientists at the University of Bonn have now, in cooperation with researchers at the University of York in the United Kingdom, analyzed the dynamics of a bacterial molecule that is involved in this process. They demonstrate that the protein grabs onto the sugar molecule with a Pac Man-like chewing motion and holds it until it can be used. Their results could help design therapeutics that could make the protein poorer at grabbing and holding and hence compromise the pathogen in the host. The study has now been published in “Biophysical Journal”.

The cells of the mouth, nose and intestinal mucosa produce large quantities of a chemical called sialic acid. Many bacteria possess a special transport system...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

12V, 48V, high-voltage – trends in E/E automotive architecture

10.01.2017 | Event News

2nd Conference on Non-Textual Information on 10 and 11 May 2017 in Hannover

09.01.2017 | Event News

Nothing will happen without batteries making it happen!

05.01.2017 | Event News

 
Latest News

Water - as the underlying driver of the Earth’s carbon cycle

17.01.2017 | Earth Sciences

Interfacial Superconductivity: Magnetic and superconducting order revealed simultaneously

17.01.2017 | Materials Sciences

Smart homes will “LISTEN” to your voice

17.01.2017 | Architecture and Construction

VideoLinks
B2B-VideoLinks
More VideoLinks >>>